Presentation Information
[O-06-5]Survey on Inebilizumab Use for NMOSD (5th interim analysis): Real-world Use of Oral Glucocorticoids
Shinya Hirota1, Kyoko Kato1, Hideki Aya1, Hideaki Hida1, Muneyoshi Kudo1, Satoshi Yuki1, Kazuo Fujihara2,3 (1.Mitsubishi Tanabe Pharma Corporation, Japan, 2.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Japan, 3.Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, Japan)